Clinical trials: Moderate to Severe Rheumatoid Arthritis
Arthritis, Rheumatoid
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
This is a secondary structured database observational study conducted in Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs, including tofacitinib, collected as part of the CorEvitas Japan RA…
- Trial name
- NCT05572567
- Where
- Japan
- Volunteers
- 1,972 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
This study is in two parts and will evaluate the safety, tolerability and efficacy of escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination with methotrexate in participants with moderate to…
- Trial name
- NCT02720120
- Testing
- Ocrelizumab
- Where
- 49 sites in Australia, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in…
- Trial name
- NCT02011334
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 25 sites in Argentina, Brazil and 4 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)
This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab)…
- Trial name
- NCT01649817
- Where
- 24 sites in Greece
- Volunteers
- 183 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Rheumatoid Arthritis
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective…
- Trial name
- UP-RISING (NCT06712628)
- Where
- 75 sites in Germany
- Volunteers
- 678 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients
To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT03254966
- Testing
- SHR0302
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) doses of LFD-200.
- Trial name
- NCT07207954
- Testing
- LFD-200, Oral Prednisone
- Where
- 10 sites in Australia, Georgia and 3 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Lifordi Immunotherapeutics, Inc.
Rheumatoid Arthritis
A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
The primary objective of this study is: To assess the efficacy and safety of dose regimens of ALX-0061 monotherapy administered subcutaneously (s.c.) to subjects with active rheumatoid arthritis (RA).
- Trial name
- NCT02287922
- Testing
- ALX-0061, Tocilizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Ablynx, a Sanofi company
Moderate and Severe Rheumatoid Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with…
- Trial name
- NCT02882087
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram [mg], 100…
- Trial name
- DARWIN1 (NCT01888874)
- Testing
- GLPG0634
- Where
- 142 sites in United States, Argentina and 20 more
- Volunteers
- 599 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks.
- Trial name
- NCT06099535
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Rheumatoid Arthritis
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to…
- Trial name
- NCT01960855
- Testing
- ABT-494
- Volunteers
- 276 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to…
- Trial name
- SELECT-NEXT (NCT02675426)
- Testing
- Upadacitinib
- Where
- 167 sites in United States, Argentina and 36 more
- Volunteers
- 661 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01665430
- Testing
- Tocilizumab
- Where
- 4 sites in Poland
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
- Trial name
- NCT01649804
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Hungary
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Dry Eye Syndromes, Sjögren Syndrome
Comparison Between Rebamipide 2% Versus Autologous Serum
Two-period, controlled, randomized and open clinical trial. The sample was composed of adult women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who attended the ocular surface office, derived…
- Trial name
- NCT03608761
- Testing
- Rebamipide, autologous serum, autologous serum and rebamipide 2%
- Where
- Argentina
- Volunteers
- 21 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
This single arm, open label study will assess the safety and efficacy, with regard to reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00848120
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Philippines
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
The purpose of this project is to evaluate the efficacy of Tocilizumab (TCZ) given as monotherapy in patients with active rheumatoid arthritis (RA) according to EULAR response at 24 weeks after treatment initiation.
- Trial name
- NCT02087696
- Testing
- Tocilizumab
- Where
- 20 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Spanish Foundation of Rheumatology
Rheumatoid Arthritis
Usability of an AI for M923 in Subjects With Moderate to Severe RA
The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)
- Trial name
- NCT02722044
- Testing
- M923, Autoinjector
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
- Trial name
- NCT04333771
- Testing
- SHR0302
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.